Curis (CRIS) Projected to Post Earnings on Wednesday

Curis (NASDAQ:CRIS) is expected to issue its results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of ($0.4325) per share and revenue of $3.2490 million for the quarter.

Curis (NASDAQ:CRIS) last released its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.13. The firm had revenue of $3.18 million for the quarter, compared to the consensus estimate of $2.86 million. On average, analysts expect Curis to post $-7 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Curis Stock Performance

Shares of CRIS opened at $0.87 on Tuesday. The firm has a market capitalization of $11.27 million, a P/E ratio of -0.24 and a beta of 3.08. Curis has a 52 week low of $0.77 and a 52 week high of $3.57. The stock has a 50 day moving average price of $1.07 and a two-hundred day moving average price of $1.41.

Institutional Investors Weigh In On Curis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC raised its holdings in Curis by 8.7% in the 3rd quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock worth $1,624,000 after purchasing an additional 78,265 shares in the last quarter. Squarepoint Ops LLC increased its position in shares of Curis by 17.9% during the third quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 8,973 shares during the period. Finally, Maverick Capital Ltd. raised its stake in Curis by 7.8% in the second quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock worth $1,472,000 after buying an additional 49,554 shares in the last quarter. 29.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $17.00.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.